Yang Doris Liu

Yang Doris Liu

Auto-generated profile, based on publicly available information

Yang Doris Liu

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC Canada

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2023 in Human Reproduction
Verified
Journal Article
Closed access
PDF file
MBMohamed Ali Bedaiwy
Mohamed Ali Bedaiwy
BFBahi Fayek
Bahi Fayek
EYEmily C Yang
Emily C Yang
MIMahmoud S Iews
Mahmoud S Iews
Mohamed ElgendiMohamed Elgendi
Mohamed Elgendi
FHFaten F Abdel Hafez
Faten F Abdel Hafez
Does the occurrence of non-visualized pregnancy loss (NVPL) affect future reproductive outcomes in patients with recurrent pregnancy loss (RPL)? The number of previous NVPLs is a significant predictor of subsequent live birth in patients with RPL. The number of preceding miscarriages is a strong indicator for future reproductive outcomes. However, NVPL particularly has been sparsely addressed in previous literature. We performed a retrospective cohort study of 1981 patients attending a specialized recurrent pregnancy loss clinic (RPL) from January 2012 to March 2021. A total of 1859 patients met the inclusion criteria of the study and were included in the analysis. Patients with a history of RPL, defined as ≥2 pregnancy losses before 20 weeks gestation, who attended a specialized RPL clinic in a tertiary care center were included. Patients’ evaluation included parental karyotyping, antiphospholipid antibodies screening, uterine cavity assessment with hysterosalpingography (HSG) or hysteroscopy, maternal thyroid stimulating hormone (TSH) testing, and serum hemoglobin A1C testing. Other investigations were performed only when indicated such as testing for inherited thrombophilias, serum prolactin, oral glucose tolerance test, and endometrial biopsy. Patients were divided into three groups; patients who experienced NVPLs only (pure NVPLs group), patients with only visualized pregnancy losses (pure VPLs group), and patients with history of both NVPLs and VPLs (mixed group). Statistical analysis was performed using Wilcoxon rank-sum tests for continuous variables and Fisher’s exact tests for categorical variables. Significance was detected when P values <0.05. A logistic regression model was used to determine the impact of NVPLs and VPLs numbers on any live birth subsequent to the initial RPL clinic visit. The prevalence of patients with pure NVPLs, pure VPLs, and mixed losses was 14.7% (274/1859), 31.8% (591/1859), and 53.5% (994/1859), respectively. The prevalence of acquired and congenital uterine anomalies diagnosed by HSG or hysteroscopy was significantly different between pure NVPLs, pure VPLs, and mixed groups (16.8% versus 23.7% versus. 20.7%, respectively P = 0.05). There were no significant differences in the results of other RPL investigations or baseline demographics between the three groups. A logistic regression model controlling for maternal age at the initial RPL clinic visit and the follow-up duration showed that the numbers of NVPLs (odds ratio (OR): 0.77, CI: 0.68–0.88) and VPLs (OR: 0.75, CI: 0.64–0.86) are strong predictors for subsequent live births after the initial RPL clinic visit (P < 0.001). The odds of having a live birth decreased by 23% and 25% with each additional NVPL and VPL, respectively. This study may be limited by its retrospective design. Some of our data, including home pregnancy tests and obstetric history, are based on patient self-reporting, which could have overstated the true prevalence of NVPLs. Another limitation is the lack of available live birth data for all patients at the time of the analysis. To our knowledge, this is the first study to examine and analyze the reproductive outcomes of patients with pure NVPLs in a substantial cohort of patients with RPL. NVPLs seem to affect future live births the same way as clinical miscarriages, which supports their inclusion in RPL definitions. This study was supported in part by Canadian Institute Heath Grant (CIHR): Reference Number/W11-179912 and Women's Health Research Institute (WHRI), Vancouver, BC, Canada. M.A.B: Research grants from Canadian Institute for Health Research (CIHR) and Ferring Pharmaceutical. M.A.B. is on the advisory board for AbbVie and Baxter. N/A.

1 October 2014 in Algological Studies
Verified
Journal Article
Closed access
JLJianguo Liu
Jianguo Liu
QLQianqian Li
Qianqian Li
QLQian Liu
Qian Liu
MHMeilin He
Meilin He
LZLitao Zhang
Litao Zhang
CHChunmei Han
Chunmei Han
Large-scale screening of wild type microalgae for favorable fast-growing oleaginous strains has been carried out in our laboratory since early 2008. Based on our rough calculation, over 30 field study trips covering routes of more than 70,000 km were launched, and over 1600 water samples were collected. More than 1200 monoclones of unicellular microalgae have been successfully isolated and purified. Of the monoclones isolated, 143 strains were selected to analyze their total lipid contents. 52 strains were used to study their abilities to produce H2 autotrophically. 11 strains were found to accumulate > 40% of total lipid per dry weight of biomass. 3 strains have the ability to accumulate > 50% of total lipid while exposed to N-deficiency. A two-stage culturing mode was developed for the three most oleaginous strains under their optimal growth conditions. Metabolic aspects of N-deprived and N-enriched Is ochrysis galbana were comparatively studied on the bioinformatic and proteomic level using two dimensional electrophoresis and matrix-assisted laser desorption/ionization-time of flight mass spectrometry. The results suggested that the glycolytic pathway and the citrate transport pathway both mitochondria and cytosol were the main routes for lipid anabolism in N-deprived I. galbana, and that the tricarboxylic acid cycle, the glyoxylate cycle and the sulfur assimilation system were the major pathways involved in lipid catabolism. For the screening of H2 producing microalgae, 28 of the 52 tested strains were found to evolve H2 under sulfur and/or nitrogen deprivation. The freshwater chlorophyte Chlorella protothecoides showed the highest H2 producing capacity among the tested algae. Chlorella autotrophica and Tetraselmis striata were two notable green marine species that produced H2 phototrophically. In terms of bioactive substances, Haematococcus pluvialis is an important species both for production of astaxanthin enriched bioproducts and for biofuels. More than 40 ecologically separated wild type strains and 12 mutants of H. pluvialis are cultivated in our laboratory. The complex, bi-phasic life cycle of H. pluvialis has been studied intensively. Natural astaxanthin and β-carotene from unicellular microalgae are produced in pilot and in industrial scale. A new variety of an aerial microalga, Trentepohlia aurea, was found to be widely distributed in snow covered mountains. T. aurea grows naturally on stone surfaces, dotting the stone in an array of saffron yellow and brownish red color due to its high carotenoid content (2.2% of dry weight), which effectively protect the cells from UV and photodamage in high altitude. T. aurea also has a powerful water-absorptive capacity and a unique cold and freezing resistance.

19 January 2024 in The Journal of Pain
Verified
Journal Article
Open access
YLYang D. Liu
Yang D. Liu
HNHeather Noga
Heather Noga
CACatherine Allaire
Catherine Allaire
MBMohamed A. Bedaiwy
Mohamed A. Bedaiwy
CLCaroline E. Lee
Caroline E. Lee
PYPaul J. Yong
Paul J. Yong
To correlate pain-related phenotyping for central nervous system sensitization in endometriosis-associated pain with mental health outcomes during the COVID-19 pandemic, the prospective Endometriosis and Pelvic Pain Interdisciplinary Cohort (ClinicalTrials.gov #NCT02911090) was linked to the COVID-19 Rapid Evidence Study of a Provincial Population-Based Cohort for Gender and Sex (RESPPONSE) dataset. The primary outcomes were depression (PHQ-9) and anxiety (GAD-7) scores during the pandemic. The explanatory variables of interest were the Central Sensitization Inventory (CSI) score (0-100) and endometriosis-associated chronic pain comorbidities/psychological variables before the pandemic. The explanatory and response variables were assessed for correlation, followed by multivariable regression analyses adjusting for PHQ-9 and GAD-7 scores pre-pandemic as well as age, body mass index, and parity. A higher CSI score and a greater number of chronic pain comorbidities before the pandemic were both positively correlated with PHQ-9 and GAD-7 scores during the pandemic. These associations remained significant in adjusted analyses. Increasing the CSI score by 10 was associated with an increase in pandemic PHQ-9 by .74 points (P < .0001) and GAD-7 by .73 points (P < .0001) on average. Each additional chronic pain comorbidity/psychological variable was associated with an increase in pandemic PHQ-9 by an average of .63 points (P = .0004) and GAD-7 by .53 points (P = .0002). Endometriosis patients with a history of central sensitization before the pandemic had worse mental health outcomes during the COVID-19 pandemic. As a risk factor for mental health symptoms in the face of major stressors, clinical proxies for central sensitization can be used to identify endometriosis patients who may need additional support. PERSPECTIVE: This article adds to the growing literature of the clinical importance of central sensitization in endometriosis patients, who had more symptoms of depression and anxiety during the COVID-19 pandemic. Clinical features of central sensitization may help clinicians identify endometriosis patients needing additional support when facing major stressors.

22 February 2024 in Human Reproduction
Verified
Journal Article
Closed access
KCKristy Cho
Kristy Cho
BFBahi Fayek
Bahi Fayek
YLYang (Doris) Liu
Yang (Doris) Liu
AAArianne Albert
Arianne Albert
EWE Wiesenthal
E Wiesenthal
MBMohamed Ali Bedaiwy
Mohamed Ali Bedaiwy
STUDY QUESTION: Is there a difference in the time interval between the first and second live births among individuals with and without recurrent pregnancy loss (RPL)? SUMMARY ANSWER: Primary RPL (two or more pregnancy losses before the first live birth) is associated with a shorter time interval between the first and second live births compared with individuals without RPL, but this association is reversed in patients with secondary RPL (RPL patients with no or one pregnancy loss before the first live birth). WHAT IS KNOWN ALREADY: There is limited information regarding the ability to have more than one child for patients with RPL. Previous studies have investigated the time to live birth and the live birth rate from the initial presentation to clinical providers. Most of the previous studies have included only patients treated at specialized RPL clinics and thus may be limited by selection bias, including patients with a more severe condition. STUDY DESIGN, SIZE, DURATION: We conducted a population-based retrospective cohort study of 184 241 participants who delivered in British Columbia, Canada, and had at least two recorded live births between 2000 and 2018. The aim was to study the differences in the time interval between the first and second live births and the prevalence of pregnancy complications in patients with and without RPL. Additionally, 198 319 individuals with their first live birth between 2000 and 2010 were studied to evaluate cumulative second live birth rates. PARTICIPANTS/MATERIALS, SETTING, METHODS: Among individuals with at least two recorded live births between 2000 and 2018, 12 321 patients with RPL and 171 920 participants without RPL were included. RPL was defined as at least two pregnancy losses before 20 weeks gestation. Patients with primary RPL had at least two pregnancy losses occurring before the first live birth, while patients with secondary RPL had no or one pregnancy loss before the first live birth. We compared the time interval from the first to second live birth in patients with primary RPL, those with secondary RPL, and participants without RPL using generalized additive models to allow for a non-linear relationship between maternal age and time interval between first and second live births. We also compared prevalence of pregnancy complications at the first and second live births between the groups using non-parametric Kruskal–Wallis H test and Fisher’s exact test for continuous and categorical variables, respectively. We assessed the cumulative second live birth rates in patients with primary RPL and those without RPL, among participants who had their first live birth between 2000 and 2010. Cox proportional hazards model was used to estimate and compare hazard ratios between the two groups using a stratified modelling approach. MAIN RESULTS AND THE ROLE OF CHANCE: The adjusted time interval between the first and second live births was the longest in patients with secondary RPL, followed by individuals without RPL, and the shortest time interval was observed in patients with primary RPL: 4.34 years (95% CI: 4.09–4.58), 3.20 years (95% CI: 3.00–3.40), and 3.05 years (95% CI: 2.79–3.32). A higher frequency of pregnancy losses was associated with an increased time interval between the first and second live births. The prevalence of pregnancy complications at the first and second live births, including gestational diabetes, hypertensive disorder of pregnancy, preterm birth, and multiple gestations was significantly higher in patients with primary RPL compared with those without RPL. The cumulative second live birth rate was significantly lower in patients with primary RPL compared with individuals without RPL. LIMITATIONS, REASONS FOR CAUTION: This study may be limited by its retrospective nature. Although we adjusted for multiple potential confounders, there may be residual confounding due to a lack of information about pregnancy intentions and other factors, including unreported pregnancy losses. WIDER IMPLICATIONS OF THE FINDINGS: The results of this study provide information that will help clinicians in the counselling of RPL patients who desire a second child. STUDY FUNDING/COMPETING INTEREST(S): This study was supported in part by a grant from the Canadian Institutes of Health Research (CIHR): Reference Number W11-179912. M.A.B. reports research grants from CIHR and Ferring Pharmaceutical. He is also on the advisory board for AbbVie, Pfizer, and Baxter. The other authors report no conflict of interest. TRIAL REGISTRATION NUMBER: NCT04360564.

18 August 2025 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
BFBahi Fayek
Bahi Fayek
YLYang Doris Liu
Yang Doris Liu
CWChristina Williams
Christina Williams
MAMohamed Elsibai Anter
Mohamed Elsibai Anter
CLCaroline Lee
Caroline Lee
MBMohamed Ali Bedaiwy
Mohamed Ali Bedaiwy

5 November 2025 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
BFBahi Fayek
Bahi Fayek
EWErica Won
Erica Won
YLYang (Doris) Liu
Yang (Doris) Liu
ASArshdeep Sidhu
Arshdeep Sidhu
MGMaya Geerts
Maya Geerts
MBMohamed Ali Bedaiwy
Mohamed Ali Bedaiwy